JP7228574B2 - レシキモドの誘導体 - Google Patents
レシキモドの誘導体 Download PDFInfo
- Publication number
- JP7228574B2 JP7228574B2 JP2020514152A JP2020514152A JP7228574B2 JP 7228574 B2 JP7228574 B2 JP 7228574B2 JP 2020514152 A JP2020514152 A JP 2020514152A JP 2020514152 A JP2020514152 A JP 2020514152A JP 7228574 B2 JP7228574 B2 JP 7228574B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- same
- deuterium
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical class C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims description 206
- 229910052805 deuterium Inorganic materials 0.000 claims description 62
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 37
- 229940124597 therapeutic agent Drugs 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 27
- 230000000155 isotopic effect Effects 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 10
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 7
- 201000005962 mycosis fungoides Diseases 0.000 claims description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 7
- 229940038671 CDX-1401 vaccine Drugs 0.000 claims description 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 6
- 101800001271 Surface protein Proteins 0.000 claims description 6
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 6
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000010348 incorporation Methods 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000006166 lysate Substances 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 238000000034 method Methods 0.000 description 48
- 235000002639 sodium chloride Nutrition 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 201000001441 melanoma Diseases 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- -1 imidazoquinolinyl Chemical group 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 229950010550 resiquimod Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 6
- MYKUTOOCWPZANP-SGEUAGPISA-N 2-methyl-1-[2-(1,1,2,2,2-pentadeuterioethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propan-2-ol Chemical compound C(C([2H])([2H])[2H])(OCC=1N(C2=C(C=NC=3C=CC=CC2=3)N=1)CC(C)(O)C)([2H])[2H] MYKUTOOCWPZANP-SGEUAGPISA-N 0.000 description 6
- 206010003571 Astrocytoma Diseases 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 4
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 4
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 4
- CXOJZGOMHAHPPW-SGEUAGPISA-N 2-methyl-1-[5-oxido-2-(1,1,2,2,2-pentadeuterioethoxymethyl)imidazo[4,5-c]quinolin-5-ium-1-yl]propan-2-ol Chemical compound C(C([2H])([2H])[2H])(OCC=1N(C2=C(C=[N+](C=3C=CC=CC2=3)[O-])N=1)CC(C)(C)O)([2H])[2H] CXOJZGOMHAHPPW-SGEUAGPISA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 229940123189 CD40 agonist Drugs 0.000 description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-ZBJDZAJPSA-N 1,1,2,2,2-pentadeuterioethanol Chemical compound [2H]C([2H])([2H])C([2H])([2H])O LFQSCWFLJHTTHZ-ZBJDZAJPSA-N 0.000 description 3
- BXNMTOQRYBFHNZ-OKMYGNPYSA-N 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-1,1,3,3,3-pentadeuterio-2-(trideuteriomethyl)propan-2-ol Chemical compound NC1=NC=2C=CC=CC=2C2=C1N=C(N2C(C(C([2H])([2H])[2H])(O)C([2H])([2H])[2H])([2H])[2H])COCC BXNMTOQRYBFHNZ-OKMYGNPYSA-N 0.000 description 3
- BXNMTOQRYBFHNZ-XERRXZQWSA-N 2-[[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]-1,1,1,3,3,3-hexadeuteriopropan-2-ol Chemical compound NC1=NC=2C=CC=CC=2C2=C1N=C(N2CC(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)COCC BXNMTOQRYBFHNZ-XERRXZQWSA-N 0.000 description 3
- VGCXGMAHQTYDJK-DICFDUPASA-N 2-chloro-2,2-dideuterioacetyl chloride Chemical group [2H]C([2H])(Cl)C(Cl)=O VGCXGMAHQTYDJK-DICFDUPASA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012648 POLY-ICLC Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229940115270 poly iclc Drugs 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- CXOJZGOMHAHPPW-GHVPMAEMSA-N 1,1,1,3,3,3-hexadeuterio-2-[dideuterio-[2-(ethoxymethyl)-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl]methyl]propan-2-ol Chemical compound C(C)OCC=1N(C2=C(C=[N+](C=3C=CC=CC2=3)[O-])N=1)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)([2H])[2H] CXOJZGOMHAHPPW-GHVPMAEMSA-N 0.000 description 2
- MYKUTOOCWPZANP-GHVPMAEMSA-N 1,1,1,3,3,3-hexadeuterio-2-[dideuterio-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]propan-2-ol Chemical compound C(C)OCC=1N(C2=C(C=NC=3C=CC=CC2=3)N=1)C(C(C([2H])([2H])[2H])(O)C([2H])([2H])[2H])([2H])[2H] MYKUTOOCWPZANP-GHVPMAEMSA-N 0.000 description 2
- BXNMTOQRYBFHNZ-SGEUAGPISA-N 1-[4-amino-2-(1,1,2,2,2-pentadeuterioethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound NC1=NC=2C=CC=CC=2C2=C1N=C(N2CC(C)(O)C)COC(C([2H])([2H])[2H])([2H])[2H] BXNMTOQRYBFHNZ-SGEUAGPISA-N 0.000 description 2
- LXQMHOKEXZETKB-AUOAYUKBSA-N 1-amino-1,1,3,3,3-pentadeuterio-2-(trideuteriomethyl)propan-2-ol Chemical compound NC(C(C([2H])([2H])[2H])(O)C([2H])([2H])[2H])([2H])[2H] LXQMHOKEXZETKB-AUOAYUKBSA-N 0.000 description 2
- LXQMHOKEXZETKB-WFGJKAKNSA-N 2-(aminomethyl)-1,1,1,3,3,3-hexadeuteriopropan-2-ol Chemical compound [2H]C([2H])([2H])C(O)(CN)C([2H])([2H])[2H] LXQMHOKEXZETKB-WFGJKAKNSA-N 0.000 description 2
- MWFMGBPGAXYFAR-WFGJKAKNSA-N 3,3,3-trideuterio-2-hydroxy-2-(trideuteriomethyl)propanenitrile Chemical compound [2H]C([2H])([2H])C(O)(C#N)C([2H])([2H])[2H] MWFMGBPGAXYFAR-WFGJKAKNSA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010086433 CDX 1307 Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 201000003731 mucosal melanoma Diseases 0.000 description 2
- HTOADVPXQZOITN-UHFFFAOYSA-N n-(4-chloroquinolin-3-yl)-2-ethoxyacetamide Chemical compound C1=CC=CC2=C(Cl)C(NC(=O)COCC)=CN=C21 HTOADVPXQZOITN-UHFFFAOYSA-N 0.000 description 2
- 229950010203 nimotuzumab Drugs 0.000 description 2
- 201000000743 nodular basal cell carcinoma Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 108700002563 poly ICLC Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CXOJZGOMHAHPPW-XERRXZQWSA-N 1,1,1,3,3,3-hexadeuterio-2-[[2-(ethoxymethyl)-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl]methyl]propan-2-ol Chemical compound C(C)OCC=1N(C2=C(C=[N+](C=3C=CC=CC2=3)[O-])N=1)CC(C([2H])([2H])[2H])(C([2H])([2H])[2H])O CXOJZGOMHAHPPW-XERRXZQWSA-N 0.000 description 1
- MYKUTOOCWPZANP-XERRXZQWSA-N 1,1,1,3,3,3-hexadeuterio-2-[[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]methyl]propan-2-ol Chemical compound C(C)OCC=1N(C2=C(C=NC=3C=CC=CC2=3)N=1)CC(C([2H])([2H])[2H])(C([2H])([2H])[2H])O MYKUTOOCWPZANP-XERRXZQWSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-CBTSVUPCSA-N 1,1-dideuterioethanol Chemical group [2H]C([2H])(C)O LFQSCWFLJHTTHZ-CBTSVUPCSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- NMYLSLKWQQWWSC-GWTDSMLYSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;phosphoric acid Chemical compound OP(O)(O)=O.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NMYLSLKWQQWWSC-GWTDSMLYSA-N 0.000 description 1
- DMNLXGKFPSZIQM-UHFFFAOYSA-N 2-chloro-N-(4-chloroquinolin-3-yl)acetamide Chemical compound ClCC(=O)NC=1C=NC2=CC=CC=C2C=1Cl DMNLXGKFPSZIQM-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102100031196 Choriogonadotropin subunit beta 3 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- OYRVWOGRRQDEQH-MLVLNPCWSA-N Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Leu Chemical compound C([C@@H](C(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCC(N)=O)C(C)CC)C1=CC=CC=C1 OYRVWOGRRQDEQH-MLVLNPCWSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000776619 Homo sapiens Choriogonadotropin subunit beta 3 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- HTOADVPXQZOITN-ZBJDZAJPSA-N N-(4-chloroquinolin-3-yl)-2-(1,1,2,2,2-pentadeuterioethoxy)acetamide Chemical compound ClC1=C(C=NC2=CC=CC=C12)NC(COC(C([2H])([2H])[2H])([2H])[2H])=O HTOADVPXQZOITN-ZBJDZAJPSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950010860 laprituximab emtansine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000001142 lung small cell carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 102000039479 opioid growth factor receptor family Human genes 0.000 description 1
- 108091056482 opioid growth factor receptor family Proteins 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- FRLRKOBIHDUBMS-UHFFFAOYSA-N tributylazanium;iodide Chemical compound [I-].CCCC[NH+](CCCC)CCCC FRLRKOBIHDUBMS-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
本出願は、2017年5月19日に出願された、米国仮特許出願第62/508,722号明細書の利益を主張する。上の出願の教示全体を、参照によって本明細書に組み込む。
用語「治療する」又は「回復させる」は、疾患(例えば、本明細書に描写した疾患若しくは障害)の発症又は進行を低下、抑制、減弱、漸減、停止、若しくは安定化させる、又は疾患の重症度を軽減する、又は疾患に関連する症状を改善することを意味する。
第1の実施態様では、本発明は、式Iの化合物:
本発明はまた、有効量の式I(例えば、本明細書の式のいずれかが含まれる)の化合物、又は前記化合物の薬学的に許容し得る塩、溶媒和物、若しくは水和物と;薬学的に許容し得る担体とを含む医薬組成物を提供する。担体は、製剤の他の成分と適合性があり、且つ薬学的に許容し得る担体の場合には医薬品中に使用される量でそのレシピエントに対して有害でないという意味で、「許容し得る」ものである。
本発明は、それを必要とする患者における、レシキモドによって有益に治療される疾患を治療する方法であって、本発明の有効量の化合物又は組成物を患者に投与するステップを含む方法を提供する。こうした疾患には、限定はされないが、腫瘍、例えば黒色腫(再発性、転移性、又は粘膜)、皮膚T細胞リンパ腫、結節型基底細胞癌、神経膠腫、退形成性星細胞腫、退形成の星細胞腫-乏突起神経膠腫、膠芽腫、膀胱癌、及び菌状息肉症;日光角化症;疣贅;アレルギー(アレルギー性鼻炎及び喘息が含まれる);結核(潜伏結核が含まれる);B型肝炎;インフルエンザ、及び他の進行悪性腫瘍が含まれる。
下に記載する実施例では、次の略語を使用する
DCM ジクロロメタン
DMF N,N-ジメチルホルムアミド
DMSO ジメチルスルホキシド
EA 酢酸エチル
FCC フラッシュカラムクロマトグラフィー
h 時間
HPLC 高速液体クロマトグラフィー
LCMS 液体クロマトグラフィー-質量分析法
mCPBA 3-クロロ過安息香酸
MeOH メタノール
NMR 核磁気共鳴
PE 石油エーテル
rt 室温
THF テトラヒドロフラン
TLC 薄層クロマトグラフィー
一般スキーム1
化合物1(2.0g、11.2mmol、1当量)とトリエチルアミン(3.4g、33.6mmol、3当量)の0℃のDCM(40mL)溶液に、塩化クロロアセチル(2.52g、22.4mmol、2当量)を添加し、得られた混合物を、室温で一晩撹拌した。この反応混合物を、1N HCl、水、及び飽和食塩水で洗浄し、真空中で濃縮した。未精製の残渣を、FCC(PE/EA:1/1で溶出する)を介して精製して、化合物3(1.2g、39.5%)を与えた。TLC:PE/EA:1/1で溶出する;化合物1 Rf=0.4;化合物3 Rf=0.6。
水素化ナトリウム(0.42g、60%(油中)、10.6mmol、3.0当量)を0℃のTHFに入れた混合物に、エタノール-d5(4、0.54g、10.6mmol、3.0当量)をTHF(10mL)に入れたものを添加し、得られた混合物を、0℃で0.5時間撹拌した。次いで、ヨウ化トリブチルアンモニウム(TBAI、0.27g)と、化合物3(0.9g、3.52mmol、1.0当量)のTHF(10mL)溶液を添加し、得られた混合物を、60℃で12時間撹拌した。この反応混合物を、水で急冷し、酢酸エチル(3×30mL)で抽出した。合わせた有機層を、水及び飽和食塩水で洗浄し、Na2SO4で乾燥させ、濾過し、真空中で濃縮した。得られた粗生成物を、FCC(PE/EA:1/1で溶出する)を介して精製して、化合物5(0.5g、53%)を提供した。TLC:PE/EA:1/1で溶出する;化合物3 Rf=0.6;化合物5 Rf=0.5。
化合物5(0.5g、1.86mmol、1当量)と化合物アミン6(0.25g、2.79mmol、1.5当量)とp-トルエンスルホン酸(50mg、当量)との混合物を、封管に入れて、125℃で15時間加熱し、次いで、この反応混合物を、室温まで冷ました。ジクロロメタンと飽和NaHCO3水溶液を添加し、得られた混合物を、15分間撹拌した。有機層を分離し、飽和NaHCO3水溶液と水で連続的に洗浄し、K2CO3で乾燥させ、濾過し、真空中で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物7(0.6g、94%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物5 Rf=0.9;化合物7 Rf=0.4。
化合物7(0.6g、1.96mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、mCPBA(0.68g、3.92mmol、2当量)を添加した。次いで、得られた混合物を、0℃で10分間、次いで室温で3時間撹拌した。この反応物を、ジクロロメタン(20mL)と飽和重炭酸ナトリウム水溶液(25mL)で希釈し、次いで、15分間撹拌した。水層を分離し、ジクロロメタン(3×25mL)で抽出し、合わせた有機分画を炭酸カリウムで乾燥させ、濾過し、減圧下で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物8(0.5g、79%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物7 Rf=0.4;化合物8 Rf=0.3。
化合物8(0.3g、0.94mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、イソシアン酸トリクロロアセチル9(0.29g、1.55mmol、1.66当量)を、撹拌しながら添加した。この反応物を、0℃で15分間、次いで55℃で1時間撹拌した。この混合物を、減圧下で濃縮し、得られた残渣を、メタノール(10mL)に溶解した。ナトリウムメトキシド(0.46g、8.43mmol、9.0当量)を添加し、得られた混合物を、55℃で2時間撹拌し、次いで、室温まで冷却した。この混合物を、減圧下で濃縮し、得られた残渣を、FCC(DCM/MeOH:15/1で溶出する)によって精製して、化合物I-1(0.15g、50 %)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物8 Rf=0.3;化合物107 Rf=0.4。CDCl3中の1H NMRを、図1Aから1Cに示す。LCMS:m/z 320.25[M+H]+.
アセトン-d6(10g、249mmol、1当量)のDCM(100mL)溶液に、0℃で、TMS-CN(29.7g、299mmol、1.2当量)と塩化亜鉛(7.9g、24.9mmol、0.1当量)を添加し、得られた混合物を、室温で一晩撹拌した。この反応物を、水で急冷し、酢酸エチル(3×30mL)で抽出した。合わせた有機層を、Na2SO4で乾燥させ、濾過し、真空中で濃縮して、未精製の化合物10(9.1g 55%)を提供し、これを、さらなる精製を行わずに次のステップに使用した。
化合物10(3.0g、44.7mmol、1当量)の0℃のTHF(30mL)溶液に、LiAlH4(3.4g、89.4mmol、2当量)を添加し、得られた混合物を、70℃で3時間撹拌した。この反応混合物を、水で急冷し、酢酸エチル(3×100mL)で抽出した。合わせた有機層を、硫酸ナトリウムで乾燥させ、濾過し、濃縮して、未精製の化合物6a(0.9g、28%)を提供し、これを、さらなる精製を行わずに次のステップに使用した。
化合物1(1.0g、5.6mmol、1当量)とトリエチルアミン(1.7g、16.8mmol、3当量)を、DCM(20mL)に溶解し、得られた混合物を、0℃まで冷却した。化合物2a(1.37g、11.2mmol、2当量)を添加し、得られた混合物を、室温で一晩撹拌した。この混合物を、1N HClで洗浄し、真空中で濃縮した。得られた粗生成物を、FCC(PE/EA:1/1で溶出する)を介して精製して、化合物5a(0.6g、40%)をもたらした。TLC:PE/EA:1/1で溶出する;化合物1 Rf=0.4;化合物5a Rf=0.5。
TEFLON加工の圧力容器に入れた、化合物5a(0.5g、1.78mmol、1当量)と化合物6a(0.25g、3.5mmol、2当量)とp-トルエンスルホン酸(0.05g)との混合物を、125℃で15時間加熱し、これらを室温まで冷ました。ジクロロメタン(50mL)と飽和NaHCO3水溶液(10mL)を添加し、得られた混合物を、15分間撹拌した。有機層を分離し、飽和NaHCO3水溶液と水で連続的に洗浄し、K2CO3で乾燥させ、濾過し、真空中で濃縮した。この生成物を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物7a(0.6g、99%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物5a Rf=0.9;化合物7a Rf=0.4。
化合物7a(0.4g、1.42mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、mCPBA(0.49g、2.84mmol、2当量)を添加した。得られた混合物を、0℃で10分間、次いで室温で3時間撹拌した。この反応混合物を、ジクロロメタン(20mL)と飽和重炭酸ナトリウム水溶液(25mL)で希釈し、次いで、15分間撹拌した。水層を分離し、ジクロロメタン(3×25mL)で抽出した。合わせた有機分画を炭酸カリウムで乾燥させ、濾過し、減圧下で濃縮した。この粗生成物を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物8a(0.2g、47%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物7a Rf=0.4;化合物8a Rf=0.3。
化合物8a(0.25g、0.84mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、イソシアン酸トリクロロアセチル9(0.26g、1.4mmol、1.66当量)を、撹拌しながら添加した。この反応物を、0℃で15分間、次いで、55℃で1時間撹拌した。この反応混合物を、減圧下で濃縮し、得られた残渣を、メタノール(10mL)に溶解した。ナトリウムメトキシド(0.41g、7.56mmol、9当量)を添加し、得られた混合物を、55℃で2時間撹拌し、室温まで冷却し、減圧下で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、104(110mg、44%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物8a Rf=0.4;I-2 Rf=0.4。MeOD中の1H NMRを、図2Aから2Cに示す。LCMS:m/z 321.3[M+H]+.
化合物10(3.0g、44.7mmol、1当量)のTHF(30mL)溶液に、0℃でLiAlD4(3.4g、89.4mmol、2当量)を添加した。この混合物を、70℃で3時間撹拌した。この反応物を、水で急冷し、酢酸エチル(3×30mL)で抽出した。有機層を、Na2SO4で乾燥させ、濾過し、濃縮して、化合物6b(1.0g、30%)を提供した。
化合物5a(0.5g、1.78mmol、1当量)と化合物6b(0.26g、3.56mmol、2当量)とp-トルエンスルホン酸(50mg)との混合物を、密封容器に入れて、125℃で15時間加熱し、室温まで冷ました。ジクロロメタンと飽和NaHCO3水溶液を添加し、この混合物を、15分間撹拌した。有機層を分離し、飽和NaHCO3水溶液と水で連続的に洗浄し、K2CO3で乾燥させ、濾過し、真空中で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物7b(0.5g、93%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物5a Rf=0.9;化合物7b Rf=0.4。
化合物7b(0.5g、1.76mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、mCPBA(0.43g、2.52mmol、2当量)を添加した。この反応物を、室温で3時間撹拌し、ジクロロメタン(20mL)、及び飽和重炭酸ナトリウム水溶液(25mL)で希釈し、15分間撹拌した。水層を分離し、ジクロロメタン(3×25mL)で抽出した。合わせた有機層を、炭酸カリウムで乾燥させ、濾過し、減圧下で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、化合物8b(0.18g、34%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物7b Rf=0.4;化合物8b Rf=0.3。
化合物8b(0.18g、0.6mmol、1当量)の0℃のジクロロメタン(10mL)溶液に、イソシアン酸トリクロロアセチル(0.19g、1.0mmol、1.66当量)を、撹拌しながら添加した。この反応混合物を、55℃で1時間加熱し、次いで、減圧下で濃縮した。得られた残渣を、メタノール(10mL)に溶解し、ナトリウムメトキシド(0.29g、5.4mmol、9当量)を添加した。この混合物を、55℃で2時間撹拌し、次いで、室温まで冷まし、減圧下で濃縮した。未精製の残渣を、FCC(DCM/MeOH:15/1で溶出する)を介して精製して、113(0.12g、67%)を提供した。TLC:DCM/MeOH:10/1で溶出する;化合物8b Rf=0.4。MeOD中の1H NMRを、図3に示す。LCMS:m/z 323.3[M+H]+.
化合物105は、実施例1のステップ1で使用される塩化クロロアセチルが塩化2-クロロアセチル-d2と置き換えられることと、実施例1のステップ2で使用されるエタノール-d5がエタノール-d2(CH3CD2OH)と置き換えられること以外は、実施例1で使用される合成手順に従って調製される。
化合物107、113、及び104、並びにレシキモド(非重水素化)を、雄のSDラットに投与し、薬物動態分析を実施した。試験される化合物のそれぞれは、0.04mg/kg用量で、IVボーラス(3ラット/群)として投与した。ラットは、試験化合物の投与の少なくとも12時間前に絶食させた。すべてのラットは、投薬後、4時間、認可されたげっ歯類用固形飼料に制約なしに接触させた。投薬後の次の時点で血液試料を採取した:5分、15分、30分、1時間、2時間、4時間、6時間、8時間、12時間、及び24時間。血液試料を、血漿に対して処理し、LC-MS/MSによって、次の薬物動態パラメータ:Cmax、T1/2、CL、Vdss、AUC0-last、AUC0-∞、MRT0-last、及びMRT0-∞について分析した。T1/2の比較を表1に示し、時間に対する血漿中濃度のグラフを図4に示す。
本発明の態様として以下のものが挙げられる。
項1
構造式I:
を有する化合物、又はその薬学的に許容し得る塩(式中、
R 1 、R 2 、及びR 3 のそれぞれは、独立に、-CH 3 、-CH 2 D、-CHD 2 、及び-CD 3 から選択され;
Y 1a 、Y 1b 、Y 2a 、Y 2b 、Y 3a 、Y 3b 、Y 4a 、Y 4b 、Y 4c 、及びY 4d のそれぞれは、独立に、水素及び重水素から選択され;
R 1 、R 2 、及びR 3 のそれぞれが-CH 3 である場合には、Y 1a 、Y 1b 、Y 2a 、Y 2b 、Y 3a 、Y 3b 、Y 4a 、Y 4b 、Y 4c 、及びY 4d の少なくとも1つは、重水素である)。
項2
R 1 、R 2 、及びR 3 のそれぞれが、独立に、-CH 3 及び-CD 3 から選択される、項1に記載の化合物。
項3
Y 1a とY 1b が同じであり;
Y 2a とY 2b が同じであり;
Y 3a とY 3b が同じであり;
Y 4a 、Y 4b 、Y 4c 、及びY 4d が同じである
項1又は2に記載の化合物。
項4
Y 4a 、Y 4b 、Y 4c 、及びY 4d のそれぞれが、水素である、項1~3のいずれか一項に記載の化合物。
項5
Y 1a とY 1b のそれぞれが重水素である、項1~4のいずれか一項に記載の化合物。
項6
Y 1a とY 1b のそれぞれが水素である、項1~4のいずれか一項に記載の化合物。
項7
Y 2a とY 2b のそれぞれが重水素である、項1~6のいずれか一項に記載の化合物。
項8
Y 2a とY 2b のそれぞれが水素である、項1~6のいずれか一項に記載の化合物。
項9
Y 3a とY 3b のそれぞれが重水素である、項1~8のいずれか一項に記載の化合物。
項10
Y 3a とY 3b のそれぞれが水素である、項1~8のいずれか一項に記載の化合物。
項11
R 1 が-CD 3 である、項1~10のいずれか一項に記載の化合物。
項12
R 1 が-CH 3 である、項1~10のいずれか一項に記載の化合物。
項13
R 2 とR 3 のそれぞれが、-CD 3 である、項1~12のいずれか一項に記載の化合物。
項14
R 2 とR 3 のそれぞれが、-CH 3 である、項1~12のいずれか一項に記載の化合物。
項15
Y 4a 、Y 4b 、Y 4c 、及びY 4d のそれぞれが、重水素であり、Y 1a とY 1b が同じであり;Y 2a とY 2b が同じであり;Y 3a とY 3b が同じであり;R 2 とR 3 が同じである、項1に記載の化合物。
項16
前記化合物が、
、又はその薬学的に許容し得る塩から選択される、項15に記載の化合物。
項17
Y 4a 、Y 4b 、Y 4c 、及びY 4d のそれぞれが、水素であり;Y 1a とY 1b が同じであり;Y 2a とY 2b が同じであり;Y 3a とY 3b が同じであり;R 2 とR 3 が同じである化合物であって、下の表:
中の任意の化合物(ここでは、重水素又はDと指定されていない任意の原子は、その天然同位体存在度で存在する)から選択される、項1に記載の化合物。
項18
前記化合物が、
又はその薬学的に許容し得る塩から選択される、項17に記載の化合物。
項19
構造式Ia:
又はその薬学的に許容し得る塩(式中:
R 1 は、-CH 3 及び-CD 3 から選択され;
Y 1a とY 1b は、同じであり;
Y 2a とY 2b は、同じである)
を有する、項1に記載の化合物。
項20
Y 2a とY 2b が、水素である、項19に記載の化合物。
項21
R 1 が-CD 3 であり、且つY 1a とY 1b のそれぞれが重水素である、項19又は20に記載の化合物。
項22
R 1 が-CH 3 であり、且つY 1a とY 1b のそれぞれが水素である、項19又は20に記載の化合物。
項23
次の構造式:
を有する、項19に記載の化合物、又はその薬学的に許容し得る塩。
項24
構造式Ib:
を有する、項1に記載の化合物、又はその薬学的に許容し得る塩(式中:
R 2 とR 3 のそれぞれは、独立に、-CH 3 及び-CD 3 から選択され;
Y 2a とY 2b は同じであり;
Y 3a とY 3b は同じである)。
項25
Y 2a とY 2b が、水素である、項24に記載の化合物。
項26
Y 3a とY 3b が、水素である、項24又は25に記載の化合物。
項27
R 2 とR 3 が同じである、項24~26のいずれか一項に記載の化合物。
項28
R 2 とR 3 が、-CH 3 である、項27に記載の化合物。
項29
R 2 とR 3 が、-CD 3 である、項27に記載の化合物。
項30
次の構造式
を有する、項24に記載の化合物、又はその薬学的に許容し得る塩。
項31
重水素又はDと指定されていない任意の原子が、その天然同位体存在度で存在する、項1~16又は19~30のいずれか一項に記載の化合物。
項32
Dと指定された各位置が、90%超の重水素取り込みを有する、項1~31のいずれか一項に記載の化合物。
項33
項1~32のいずれか一項に記載の化合物と;薬学的に許容し得る担体とを含む医薬組成物。
項34
癌、自己免疫疾患、及び感染症から選択される疾患を治療する方法であって、項1~32のいずれか一項に記載の化合物、又は項33に記載の医薬組成物を、それを必要とする対象に投与するステップを含む方法。
項35
前記疾患が、皮膚T細胞リンパ腫である、項34に記載の方法。
項36
対象における、ある抗原に対する免疫応答を増強させる方法であって、前記抗原と、項1~32のいずれか一項に記載の化合物又は項33に記載の医薬組成物とを、対象に同時投与するステップを含む方法。
項37
前記抗原が、癌抗原、インフルエンザ抗原、及びB型肝炎ウイルス抗原から選択される、項36に記載の方法。
項38
前記癌抗原が、NY-ESO-1タンパク質、NY-ESO-1bペプチド、gp100、MAGE-3、CDX-1401、LPV7、及び自己腫瘍ライセートから選択される、項36に記載の方法。
項39
癌を治療する方法であって、有効量の項1~32のいずれか一項に記載の化合物、又は項33に記載の医薬組成物と;免疫療法剤及び治療用抗体から選択される第2の治療薬とを、それを必要とする対象に同時投与するステップを含む方法。
項40
前記免疫療法剤が、チェックポイント阻害剤である、項39に記載の方法。
項41
前記治療用抗体が、EGFRに対して選択的である抗体及びHer 2に対して選択的である抗体から選択される、項39に記載の方法。
Claims (42)
- Y1aとY1bが同じであり;
Y2aとY2bが同じであり;
Y3aとY3bが同じであり;
Y4a、Y4b、Y4c、及びY4dが同じである
請求項1に記載の化合物。 - Y4a、Y4b、Y4c、及びY4dのそれぞれが、水素である、請求項1又は2に記載の化合物。
- Y1aとY1bのそれぞれが重水素である、請求項1~3のいずれか一項に記載の化合物。
- Y1aとY1bのそれぞれが水素である、請求項1~4のいずれか一項に記載の化合物。
- Y2aとY2bのそれぞれが重水素である、請求項1~5のいずれか一項に記載の化合物。
- Y2aとY2bのそれぞれが水素である、請求項1~5のいずれか一項に記載の化合物。
- Y3aとY3bのそれぞれが重水素である、請求項1~7のいずれか一項に記載の化合物。
- Y3aとY3bのそれぞれが水素である、請求項1~7のいずれか一項に記載の化合物。
- R1が-CD3である、請求項1~9のいずれか一項に記載の化合物。
- R1が-CH3である、請求項1~9のいずれか一項に記載の化合物。
- R2とR3のそれぞれが、-CD3である、請求項1~10のいずれか一項に記載の化合物。
- R2とR3のそれぞれが、-CH3である、請求項1~10のいずれか一項に記載の化合物。
- Y4a、Y4b、Y4c、及びY4dのそれぞれが、重水素であり、Y1aとY1bが同じであり;Y2aとY2bが同じであり;Y3aとY3bが同じであり;R2とR3が同じである、請求項1に記載の化合物。
- Y2aとY2bが、水素である、請求項18に記載の化合物。
- R1が-CD3であり、且つY1aとY1bのそれぞれが重水素である、請求項18又は19に記載の化合物。
- R1が-CH3であり、且つY1aとY1bのそれぞれが水素である、請求項18又は19に記載の化合物。
- Y2aとY2bが、水素である、請求項23に記載の化合物。
- Y3aとY3bが、水素である、請求項23又は24に記載の化合物。
- R2とR3が同じである、請求項23~25のいずれか一項に記載の化合物。
- R2とR3が、-CH3である、請求項26に記載の化合物。
- R2とR3が、-CD3である、請求項26に記載の化合物。
- 重水素又はDと指定されていない任意の原子が、その天然同位体存在度で存在する、請求項1~15又は18~29のいずれか一項に記載の化合物。
- Dと指定された各位置が、90%超の重水素取り込みを有する、請求項1~30のいずれか一項に記載の化合物。
- 請求項1~30のいずれか一項に記載の化合物と;薬学的に許容し得る担体とを含む医薬組成物。
- 癌、自己免疫疾患、及び感染症から選択される疾患を治療するための請求項32に記載の医薬組成物。
- 前記疾患が、皮膚T細胞リンパ腫である、請求項33に記載の医薬組成物。
- 対象における、ある抗原に対する免疫応答を増強させるための組成物であって、前記組成物は、請求項1~30のいずれか一項に記載の化合物を含み、前記抗原と共に対象に同時投与される、組成物。
- 前記抗原が、癌抗原、インフルエンザ抗原、及びB型肝炎ウイルス抗原から選択される、請求項35に記載の組成物。
- 前記癌抗原が、NY-ESO-1タンパク質、NY-ESO-1bペプチド、gp100、MAGE-3、CDX-1401、LPV7、及び自己腫瘍ライセートから選択される、請求項36に記載の組成物。
- 癌を治療するための請求項32に記載の医薬組成物であって、免疫療法剤及び治療用抗体から選択される第2の治療薬と共にそれを必要とする対象に同時投与される、医薬組成物。
- 前記免疫療法剤が、チェックポイント阻害剤である、請求項38に記載の医薬組成物。
- 前記治療用抗体が、EGFRに対して選択的である抗体及びHer 2に対して選択的である抗体から選択される、請求項38に記載の医薬組成物。
- チェックポイント阻害剤が、PD-1阻害剤である、請求項39に記載の医薬組成物。
- PD-1阻害剤が、ペムブロリズマブ及びニボルマブから選択される、請求項41に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508722P | 2017-05-19 | 2017-05-19 | |
US62/508,722 | 2017-05-19 | ||
PCT/US2018/033493 WO2018213769A1 (en) | 2017-05-19 | 2018-05-18 | Derivatives of resiquimod |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020520993A JP2020520993A (ja) | 2020-07-16 |
JP2020520993A5 JP2020520993A5 (ja) | 2021-07-26 |
JP7228574B2 true JP7228574B2 (ja) | 2023-02-24 |
Family
ID=62528901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020514152A Active JP7228574B2 (ja) | 2017-05-19 | 2018-05-18 | レシキモドの誘導体 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11274099B2 (ja) |
EP (1) | EP3625231B1 (ja) |
JP (1) | JP7228574B2 (ja) |
KR (1) | KR102650538B1 (ja) |
CN (2) | CN111094282B (ja) |
AU (1) | AU2018270266B2 (ja) |
BR (1) | BR112019024177A2 (ja) |
CA (1) | CA3063953A1 (ja) |
DK (1) | DK3625231T3 (ja) |
ES (1) | ES2928723T3 (ja) |
IL (1) | IL270703B2 (ja) |
MX (1) | MX2019013769A (ja) |
PH (1) | PH12019502544A1 (ja) |
WO (1) | WO2018213769A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111094282B (zh) | 2017-05-19 | 2023-06-16 | 智优有限公司 | 瑞喹莫德的衍生物 |
WO2023041982A1 (en) * | 2021-09-17 | 2023-03-23 | Birdie Biopharmaceuticals, Inc. | Combination therapy with deuterated imidazoquinolines |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016515538A (ja) | 2013-03-15 | 2016-05-30 | ブレット バイオテクノロジー、 インク.Bullet Biotechnology, Inc. | 特異的な多価ウイルス様粒子ワクチンおよびその使用 |
WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
EP0872478B1 (en) * | 1991-03-01 | 2002-12-18 | Minnesota Mining And Manufacturing Company | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
KR100235389B1 (ko) * | 1991-03-01 | 1999-12-15 | 스프레이그 로버트 월터 | 1-치환된, 2-치환된 1H-이미다조[4,5-c]퀴놀린-4-아민 |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
HUP9904665A3 (en) | 1996-10-25 | 2000-11-28 | Minnesota Mining And Mfg Co Sa | Immune response modifier compounds for treatment of th2 mediated and related diseases |
AU776654B2 (en) | 1999-01-08 | 2004-09-16 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
RS83503A (en) | 2001-05-03 | 2006-10-27 | F. Hoffmann-La Roche Ag. | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20060183767A1 (en) | 2003-01-06 | 2006-08-17 | Eugene Mandrea | Methods of stimulating immune response in certain individuals |
EP2583678A3 (en) | 2004-06-24 | 2013-11-13 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
US20180311505A1 (en) * | 2015-11-05 | 2018-11-01 | The General Hospital Corporation | Methods for treating cancer by enhancing intratumoral immune response |
CN111094282B (zh) | 2017-05-19 | 2023-06-16 | 智优有限公司 | 瑞喹莫德的衍生物 |
-
2018
- 2018-05-18 CN CN201880044288.9A patent/CN111094282B/zh active Active
- 2018-05-18 MX MX2019013769A patent/MX2019013769A/es unknown
- 2018-05-18 KR KR1020197037270A patent/KR102650538B1/ko active IP Right Grant
- 2018-05-18 JP JP2020514152A patent/JP7228574B2/ja active Active
- 2018-05-18 CN CN202310632172.XA patent/CN116854686A/zh active Pending
- 2018-05-18 US US16/612,216 patent/US11274099B2/en active Active
- 2018-05-18 EP EP18729301.4A patent/EP3625231B1/en active Active
- 2018-05-18 ES ES18729301T patent/ES2928723T3/es active Active
- 2018-05-18 CA CA3063953A patent/CA3063953A1/en active Pending
- 2018-05-18 DK DK18729301.4T patent/DK3625231T3/da active
- 2018-05-18 AU AU2018270266A patent/AU2018270266B2/en active Active
- 2018-05-18 WO PCT/US2018/033493 patent/WO2018213769A1/en unknown
- 2018-05-18 BR BR112019024177-9A patent/BR112019024177A2/pt unknown
-
2019
- 2019-11-14 PH PH12019502544A patent/PH12019502544A1/en unknown
- 2019-11-17 IL IL270703A patent/IL270703B2/en unknown
-
2022
- 2022-02-04 US US17/665,104 patent/US20230002370A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016515538A (ja) | 2013-03-15 | 2016-05-30 | ブレット バイオテクノロジー、 インク.Bullet Biotechnology, Inc. | 特異的な多価ウイルス様粒子ワクチンおよびその使用 |
WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
Non-Patent Citations (1)
Title |
---|
公益社団法人 日本化学会,化学便覧 応用化学編 第7版,2014年,第252、253頁 |
Also Published As
Publication number | Publication date |
---|---|
BR112019024177A2 (pt) | 2020-06-02 |
CN116854686A (zh) | 2023-10-10 |
JP2020520993A (ja) | 2020-07-16 |
CA3063953A1 (en) | 2018-11-22 |
US20200207757A1 (en) | 2020-07-02 |
PH12019502544A1 (en) | 2020-07-13 |
ES2928723T3 (es) | 2022-11-22 |
WO2018213769A1 (en) | 2018-11-22 |
IL270703B2 (en) | 2023-07-01 |
KR102650538B1 (ko) | 2024-03-21 |
MX2019013769A (es) | 2020-07-20 |
US11274099B2 (en) | 2022-03-15 |
KR20200038889A (ko) | 2020-04-14 |
CN111094282A (zh) | 2020-05-01 |
EP3625231A1 (en) | 2020-03-25 |
DK3625231T3 (da) | 2022-10-31 |
RU2019141473A (ru) | 2021-06-21 |
CN111094282B (zh) | 2023-06-16 |
IL270703A (en) | 2020-01-30 |
IL270703B1 (en) | 2023-03-01 |
EP3625231B1 (en) | 2022-07-20 |
US20230002370A1 (en) | 2023-01-05 |
RU2019141473A3 (ja) | 2021-09-17 |
AU2018270266A1 (en) | 2020-01-16 |
AU2018270266B2 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6063455B2 (ja) | 重水素化されたイバカフトルの誘導体 | |
US20230002370A1 (en) | Derivatives of resiquimod | |
KR101649332B1 (ko) | 치환된 다이옥소피페리디닐 프탈이미드 유도체 | |
US9045453B2 (en) | Substituted dioxopiperidinyl phthalimide derivatives | |
US20130150408A1 (en) | Substituted dioxopiperidinyl phthalimide derivatives | |
US9108902B2 (en) | Deuterated 2-amino-3-hydroxypropanoic acid derivatives | |
EP2970209B1 (en) | Deuterated palbociclib with improved metabolic stability | |
EA032639B1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
TWI755788B (zh) | 類鐸受體促效劑 | |
US10759721B2 (en) | Deuterated CFTR potentiators | |
RU2808163C2 (ru) | Производные резиквимода | |
AU2020372832A1 (en) | 4-Amino-imidazoquinoline compounds and use thereof | |
JP6654223B2 (ja) | 重水素化されたcftr増強物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210514 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210514 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7228574 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |